In vivo efficacy was evaluated in mouse models of postoperative ileus (POI; 10, 20 or 30 mg/kg), age-related sarcopenia (10 mg/kg/day for 4 weeks) and cancer cachexia (10 or 30 mg/kg/day from Days 9 to 24 after CT26 tumour induction).<h4>Results</h4>KARIs directly interacted with key GHSR-1a residues (Phe279) and increased calcium influx (EC<sub>50</sub>: KARI 101 = 1.83 ± 1.05 μM; KARI 201 = 3.36 ± 1.09 μM). The gene discussed is GHSR; the disease is cancer.